Drug Trial Radar · NCT03491462
Arimoclomol in Amyotropic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Jul 31, 2018
Primary completion
Dec 18, 2020
Study completion Dec 18, 2020
Sponsor
- Lead sponsor
- ZevraDenmarkIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ArimoclomolDrug
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
PlaceboDrug
2 matched placebo capsules taken 3 times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined Assessment of Function and Survival (CAFS)Time frame: Over 76 Weeks
Locations
29 sites in 12 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center
Phoenix, Arizona
HonorHealth Neurology
Phoenix, Arizona
UC Irvine Health ALS and Neuromuscular Center
Orange, California
University of Miami
Miami, Florida
University of Kansas Medical Center (KUMC) - Landon Center on Aging
Kansas City, Kansas
Hospital for Special Surgery
New York, New York
Providence Brain & Spine Institute
Portland, Oregon
University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
University of Virginia Health System
Charlottesville, Virginia
Catholic University Leuven
Leuven, Belgium
London Health Sciences Centre
London, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac
Montpellier, France
Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422
Paris, France
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen
Berlin, Germany
Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie
Hanover, Germany
Universitaetsklinikum Ulm - Klinik fuer Neurologie
Ulm, Germany
Instituti Clinica Scientifici Maugeri - IRCCS
Milan, Italy
Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino
Torino, Italy
University Medical Center Utrecht
Utrecht, Netherlands
Centrum Medyczne NeuroProtect
Warsaw, Poland
Citi Clinic
Warsaw, Poland
Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11
Barcelona, Spain
Hospital Carlos III - Hospital Universitario La Paz, ALS Unit
Madrid, Spain
Umeå University Hospital
Umeå, Sweden
Kantonsspital St.Gallen, Muskelzentrum/ALS Clinic
Sankt Gallen, Switzerland
Leonard Wolfson Experimental Neurology Centre
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.